Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapywhich Patients Will Benefit From Surgery

NCT05285332 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT05285332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05285332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapywhich Patients Will Benefit From Surgery
Lead sponsor
Changhai Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2022
Completion date
May 1, 2031
Enrollment
362 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, metastatic breast cancer, survival, treatment